134 related articles for article (PubMed ID: 11886813)
1. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
Hirayama F; Koshio H; Katayama N; Kurihara H; Taniuchi Y; Sato K; Hisamichi N; Sakai-Moritani Y; Kawasaki T; Matsumoto Y; Yanagisawa I
Bioorg Med Chem; 2002 May; 10(5):1509-23. PubMed ID: 11886813
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template.
Hirayama F; Koshio H; Katayama N; Ishihara T; Kaizawa H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kurihara H; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2003 Feb; 11(3):367-81. PubMed ID: 12517432
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
Hirayama F; Koshio H; Ishihara T; Watanuki S; Hachiya S; Kaizawa H; Kuramochi T; Katayama N; Kurihara H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2002 Aug; 10(8):2597-610. PubMed ID: 12057649
[TBL] [Abstract][Full Text] [Related]
4. Discovery of R-142086 as a factor Xa (FXa) inhibitor: syntheses and structure-activity relationships of cinnamyl derivatives.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Niitsu Y; Asai F; Ishizuka T; Fujimoto K
Chem Pharm Bull (Tokyo); 2009 Jan; 57(1):22-33. PubMed ID: 19122312
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice.
Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y; Iizumi Y
Jpn J Pharmacol; 1998 Oct; 78(2):191-7. PubMed ID: 9829622
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
Kawasaki T; Sato K; Sakai Y; Hirayama F; Koshio H; Taniuchi Y; Matsumoto Y
Thromb Haemost; 1998 Feb; 79(2):410-6. PubMed ID: 9493600
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa.
Taniuchi Y; Sakai Y; Hisamichi N; Kayama M; Mano Y; Sato K; Hirayama F; Koshio H; Matsumoto Y; Kawasaki T
Thromb Haemost; 1998 Mar; 79(3):543-8. PubMed ID: 9531037
[TBL] [Abstract][Full Text] [Related]
8. Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.
Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Nagamochi M; Kobayashi S; Komoriya S; Yokomizo A; Muto R; Yamaguchi M; Osanai K; Suzuki M; Kanno H
Bioorg Med Chem; 2009 Feb; 17(3):1193-206. PubMed ID: 19128974
[TBL] [Abstract][Full Text] [Related]
9. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
Hara T; Yokoyama A; Morishima Y; Kunitada S
Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
[TBL] [Abstract][Full Text] [Related]
10. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.
Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y
Eur J Pharmacol; 1998 Apr; 347(2-3):231-6. PubMed ID: 9653887
[TBL] [Abstract][Full Text] [Related]
11. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
Rezaie AR
Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
[TBL] [Abstract][Full Text] [Related]
12. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
[TBL] [Abstract][Full Text] [Related]
13. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
Koshio H; Hirayama F; Ishihara T; Kaizawa H; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Uemura T; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2004 Oct; 12(20):5415-26. PubMed ID: 15388168
[TBL] [Abstract][Full Text] [Related]
14. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.
Imaeda Y; Miyawaki T; Sakamoto H; Itoh F; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
Bioorg Med Chem; 2008 Mar; 16(5):2243-60. PubMed ID: 18077174
[TBL] [Abstract][Full Text] [Related]
15. Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.
Shi Y; Zhang J; Shi M; O'Connor SP; Bisaha SN; Li C; Sitkoff D; Pudzianowski AT; Chong S; Klei HE; Kish K; Yanchunas J; Liu EC; Hartl KS; Seiler SM; Steinbacher TE; Schumacher WA; Atwal KS; Stein PD
Bioorg Med Chem Lett; 2009 Aug; 19(15):4034-41. PubMed ID: 19541481
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs.
Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Ichihara M; Matsumoto Y
Eur J Pharmacol; 1998 May; 350(1):87-91. PubMed ID: 9683019
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
[TBL] [Abstract][Full Text] [Related]
18. Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.
Shi Y; Li C; O'Connor SP; Zhang J; Shi M; Bisaha SN; Wang Y; Sitkoff D; Pudzianowski AT; Huang C; Klei HE; Kish K; Yanchunas J; Liu EC; Hartl KS; Seiler SM; Steinbacher TE; Schumacher WA; Atwal KS; Stein PD
Bioorg Med Chem Lett; 2009 Dec; 19(24):6882-9. PubMed ID: 19896847
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
[TBL] [Abstract][Full Text] [Related]
20. Cinnamylindoline derivatives: synthesis and factor Xa (FXa) inhibitory activities.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1494-504. PubMed ID: 17917295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
